CTOs on the Move

DiaCarta

www.diacarta.com

 
DiaCarta is a translational genomics and personalized diagnostics company that provides ultra-sensitive detection tools for cancer diagnosis, therapy identification and prognosis monitoring. Our mission is to provide ultra-sensitive and advanced technologies that will redefine the way molecular diagnostics and translational genomics impact healthcare treatment plans and the well-being of individuals around the world.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.diacarta.com
  • 2600 Hilltop Drive
    Richmond, CA USA 94806
  • Phone: 800.246.8878

Executives

Name Title Contact Details
Michael Sha
Chief Technology Officer and Senior Vice President of Research & Development Profile

Funding

DiaCarta raised $45M on 02/12/2018

Similar Companies

Morphotek

Morphotek is a Exton, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

OWKIN

OWKIN builds mathematical models and algorithms that can interpret omics, visual data, biostatistics and patient profiles like never before. With OWKIN, patients directly benefit with more effective treatments.

SyntheZyme

SyntheZyme develops bio-based products and technologies with a unique and competitive cost/performance. We work closely together with our industrial partners for the manufacture and marketing of our bio-based commodity and specialty products for the global market. We seek to complement our core competencies with those of our strategic, industrial partners. The success of our business is based on our capabilities to structure and operate entrepreneurial partnerships. SyntheZyme’s scientists and engineers have a deep knowledge in chemistry, synthetic biology, fermentation engineering and materials science with process know-how

Verano Holdings

Verano™ Holdings is a national, vertically-integrated operator of licensed cannabis cultivation, manufacturing and retail facilities dedicated to improving lives by providing safe access to effective organic cannabis products that enhance health and wellness and by positively impacting the communities it serves.

Rani Therapeutics

Rani Therapeutics has developed the RaniPill™, a platform technology for the oral delivery of biologic drugs. Millions of patients with chronic conditions require biologic drugs that today can only be injected. These injections are painful and inconvenient and often affect both patient compliance and quality of life. The pharma industry has been searching for decades to convert injectables into pills, and we believe the solution is the RaniPill™ capsule. We have demonstrated bioavailability similar to subcutaneous injections in both preclinical and clinical studies. Rani has an internal pipeline of molecules, and active collaborations with Novartis and Takeda. The research and technology behind Rani Therapeutics came out of InCube Labs, a multi-disciplinary life sciences R&D lab focused on breakthrough medical innovations. InCube is led by Mir Imran, a prolific medical inventor, entrepreneur, and investor.